CD19 CAR-NK cells therapy(Rongu Biotechnology)

N/A

Report date: 2024/07/31 15:37:57

Base Information

Drug NameCD19 CAR-NK cells therapy(Rongu Biotechnology)
Drug Alias NameRG-19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD19Natural killer cell replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHangzhou Rongu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Rongu Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A